Telos Capital Management Inc. Raises Stake in Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Jul 25th, 2023

Telos Capital Management Inc. boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 0.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 75,276 shares of the company’s stock after acquiring an additional 104 shares during the period. Johnson & Johnson accounts for about 1.6% of Telos Capital Management Inc.’s investment portfolio, making the stock its 13th largest holding. Telos Capital Management Inc.’s holdings in Johnson & Johnson were worth $11,668,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of JNJ. GW&K Investment Management LLC purchased a new position in Johnson & Johnson in the fourth quarter worth about $35,000. Dark Forest Capital Management LP grew its stake in shares of Johnson & Johnson by 1,044.4% in the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock worth $36,000 after acquiring an additional 188 shares during the period. Retirement Financial Solutions LLC bought a new stake in Johnson & Johnson during the fourth quarter valued at approximately $40,000. Ruedi Wealth Management Inc. bought a new stake in Johnson & Johnson during the fourth quarter valued at approximately $42,000. Finally, Kepos Capital LP bought a new stake in Johnson & Johnson during the fourth quarter valued at approximately $45,000. 67.57% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 0.5 %

JNJ stock opened at $171.10 on Tuesday. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $181.04. The stock has a market capitalization of $444.64 billion, a price-to-earnings ratio of 34.64, a price-to-earnings-growth ratio of 2.88 and a beta of 0.55. The firm’s fifty day simple moving average is $160.60 and its two-hundred day simple moving average is $161.20.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings results on Thursday, July 20th. The company reported $2.80 EPS for the quarter, topping analysts’ consensus estimates of $2.62 by $0.18. The firm had revenue of $25.53 billion for the quarter, compared to analysts’ expectations of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 37.01%. The business’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.59 earnings per share. As a group, analysts anticipate that Johnson & Johnson will post 10.75 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be issued a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.78%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s payout ratio is presently 96.36%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on JNJ. Morgan Stanley reiterated an “equal weight” rating and issued a $187.00 price target on shares of Johnson & Johnson in a research report on Friday. StockNews.com assumed coverage on shares of Johnson & Johnson in a research report on Thursday, May 18th. They issued a “strong-buy” rating for the company. Citigroup assumed coverage on shares of Johnson & Johnson in a report on Tuesday, May 30th. They issued a “buy” rating and a $185.00 target price on the stock. Atlantic Securities lowered their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a report on Wednesday, April 19th. Finally, Credit Suisse Group boosted their target price on shares of Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a report on Friday. Eight equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $171.60.

Insider Transactions at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the transaction, the executive vice president now directly owns 65,934 shares in the company, valued at $10,549,440. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.20% of the company’s stock.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.